Skip to content
The Bio Report cover art

All episodes

The Bio Report, 641 episodes. Page 5 of 7.

#
Title
401

Targeting the Right Proteins to Treat Neurological Diseases

402

A Treat Locally, Act Globally Strategy for Treating Cancer

403

Squeezing New Possibilities into Cell Therapies

404

Industry Calls for New Incentives to Spur Development of New Antibiotics

405

Company Seeks to Prove Marine-Derived Alzheimer’s Drug Is No Fish Story

406

Targeting the Plasma Proteome to Address Diseases of Aging

407

Teaching Scientists to Be Effective Communicators

408

Designing Small-Molecule, Immuno-Oncology Drugs That Act Like Biologics

409

Biohacking for the Masses

410

A Hearts and Minds Strategy for Cardiovascular Disease

411

A Drug Hunter Finds Greater Freedom at a Nonprofit Institute

412

Attacking IBD Through a Novel Pathway

413

Writing the Future of Drug Research with Bioink

414

An Effort to Develop Safer and More Effective Immunotherapies

415

The Year in Biotech and What to Watch in 2019

416

Why One Investor Is Betting on Platform Technologies to Change the World

417

Price Transparency and a Healthcare Policy Analyst’s Brush with the Healthcare System

418

How a Leading Health Sciences University is Working to Address Homelessness

419

Gecko Looks to Broad Applications in Tissue Reconstruction

420

The Search for Mediators of Aging

421

Using Drug Delivery Technology to Improve ADHD Therapies

422

How One Company Is Targeting a Growing Opportunity in Women’s Reproductive Health

423

Why an HIV Drug in Development Could Change How Cancer Is Treated

424

How the Rise of the Patient-Consumer Is Changing Clinical Trials

425

Bringing Real-World Monitoring to Autoimmune Disease

426

Using Real-World Evidence to Improve Drug Development

427

Enlisting Immunotherapies in the Fight Against Infectious Diseases

428

Tackling the Problem of Resistance in Chemotherapy

429

Engineering Bacteria for Therapeutic Benefit

430

The Promise of Organ-on-a-Chip Technology to Improve Drug Development

431

Harnessing AI to Fight Diseases of Aging

432

Transforming Clinical Trials with Digital Health Technologies

433

Why Foresite Capital is Betting Big on the Convergence of AI and Biotech

434

Why Public Health Systems Need to Be Better Prepared for Extreme Weather Events

435

Predicting the Unpredictable Off-Target Activities of Drugs

436

Why Clinics Providing Stem Cell Therapies not Approved by the FDA Are Creating Growing Concern

437

Making Biomedical Discoveries Sooner

438

Reinventing Drug Discovery with AI

439

Carrying Therapeutic Payloads Across the Blood-Brain Barrier

440

Harnessing Bacteria to Improve Skin Health

441

How One Accelerator Tries to Give Early-Stage Drug Developers an Edge

442

Making Synthetic Biology a Commercial Reality

443

Why Behavioral Economics May Turn Irrational Patients Rational

444

Pushing the Frontiers of Longevity

445

Is Hearing Loss a Necessary Price for Children to Pay for Life-Saving Chemotherapies

446

Why Diagnostics May Be Critical to Reshaping Alzheimer’s Drug Development

447

Why the Diversity of Genomic Data Matters

448

Why Biomarkers May Be the Key to Immuno-Oncology Success

449

Seeing Virtue in Patients

450

When Science Becomes a Cause

451

The Pursuit of Healthier, Safer, and More Humane Meat

452

A Hidden Killer and Why Patients Face Barriers to Accessing Promising New Drugs for It

453

Targeting the Regulators of Genes to Treat Disease

454

Price-Fixing Case Against Generic Drugmakers Widens

455

Outcomes Erode for Newborns and Mothers in Rural America as Hospitals Lose Obstectric Services

456

Why Drug Companies May Soon Become Health Technology Companies

457

After Facing Death, Former HR Director Helps Others Get a New Perspective on Life

458

Putting Physics to Work in the Fight Against Cancer

459

Why Aging Might Best Be Thought of as a Disease

460

Looking for a Better Alternative to Chemotherapy for AL Amyloidosis

461

A University Spin-Out that Incubates University Spin Outs

462

Understanding the Challenges and Opportunities of Patient-Centric Outcomes

463

How CellMax Hopes to Change the Diagnosis Cancer with Inexpensive Liquid Biopsy

464

How Surveillance and Data Are Bringing Precision to the Treatment of Prostate Cancer

465

Why Life Sciences M&A Should Heat up This Year

466

The Outlook for Biotech in 2018

467

The Year in Biotech and What to Watch in 2018

468

The Year in Immuno-Oncology and What to Watch in 2018

469

What the Approval of the First Digital Pill Means for the Future of Healthcare

470

Why Public Health Systems Need to Be Better Prepared for Extreme Weather Events

471

Former CDC Director Takes on World’s Leading Cause of Death

472

How a Public-Private Consortium Is Revolutionizing Cancer Drug Discovery

473

How Faulty Thinking Can Derail Life Sciences M&A Deals

474

Targeting Drug-Resistant Bacteria with an Ancient Enemy

475

A Bioelectronic Approach to Treating Autoimmune Diseases

476

Harnessing Patient Data to Improve Drug Development Efficiency

477

How Colorifix Is Trying to Turn the Textile Industry Green

478

Targeting Patients as Sick as Dogs

479

A Strategic Investor’s View of the Biotech Investment Landscape

480

Bringing Gender Diversity into Biotech Boardrooms

481

Why the FDA May Need to Rethink Its Approach to Gene and Cell Therapy

482

VBL Targets Brain and other Cancers with Novel Immunotherapy

483

What Will It Take to Transform Healthcare to a System Focused on Prediction and Prevention

484

Can a Direct Pitch to Patients Drive a Home Run for Obesity Drug

485

Why Companies Across Industries Need to Develop a Bio Strategy

486

Economist Argues Maximizing Shareholder Value Hurts Drug Innovation

487

Partnership Drives Development of Antibiotic to Combat Resistant Gonorrhea

488

CIRM-Funded Pipeline of Regenerative Therapies Advances

489

Technology Allows Drugmakers to Tag and Authenticate Individual Pills

490

Harnessing Mosquitoes to Fight the Spread of Infectious Disease

491

Biotech Industry Moves Towards a Patent Cliff

492

PvP Takes a Unique Approach to Treating an Autoimmune Disease

493

Uncertainty Hangs over the Biotech Sector

494

What Others Can Learn from COI’s Approach to Cost-Efficient Drug Development

495

Dyadic Seek to Bring Disruptive Technology to Biomanufacturing

496

Enlisting the Immune System in the Battle Against Alzheimer’s

497

Overcoming the Delivery Challenges of Gene Therapy

498

Brexit Sparks Battle to House the EMA

499

New Safety Concerns Identified After FDA Approval of One in Three Drugs

500

Why Climate Change Is a Public Health Concern